What Happened?
Framingham, MA-based Arch-Therapeutics Appointed Michael Abrams as Chief Financial Officer
About the Company
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch`s development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2
About the Person
Michael Abrams is Chief Financial Officer at Arch Therapeutics. Previously, Michael held various senior HR leadership roles in the industry.
Info Source
News
Short Profile